

Sous le haut patronage de sa Majesté le Roi Mohammed VI



20TH International Conference on Behçet's Disease

18-20 SEPTEMBER 2024

HOTEL SAVOY LE GRAND

MARRAKECH

Tuesday 17th September 2024

15:00 - 20:00	Registration
17:00 - 18:30	Executive Committee Meeting - room ASNI
18:30 - 19:30	Council Meeting
20:30	President's Dinner 

Wednesday 18th September 2024

08:00 - 19:00	Registration	
08:45 - 09:00	President's Welcome Speech President of ISBD Presidente of the Conference President of Moroccan Society of Internal Medicine	M. Schirmer (Austria) Z. Tazi Mezalek (Morocco) M. Adnaoui (Morocco)
09:00 - 09:35	Special Lecture : Netosis in auto-inflammation Chairs : M. Schirmer (Austria), M. Adnaoui (Morocco)	P. Hasler (Switzerland)
09:35 - 11:20	Scientific Session 1: Basic Science Chairs : M. Schirmer (Austria), M. Adnaoui (Morocco)	
09:35 - 09:55	Immunopathogenesis of Behçet's disease	PM. van Hagen (Netherlands)
09:55 - 10:15	NET's in Behçet disease	A. LeJoncour (France)
10:15 - 10:35	Microbiome and microbes in Behçet's disease	A. Bettioli (Italy)
10:35 - 11:20	Oral presentations - Session 1	
11:20 - 11:45	Coffee Break 	
11:45 - 13:25	Scientific Session 2 : Epidemiology & Genetics Chairs : L. Guillevin (France), H. El Kabli (Morocco)	
11:45 - 12:05	Epidemiologic and genetic contribution to the phenotype of Behçet's disease	A. Gul (Turkey)
12:05 - 12:25	Registries in Behçet's disease	L. Cantarini (Italy)
12:25 - 12:45	Pathogenesis of non-infectious uveitis elucidated by recent findings	P. Haris (UK)
12:45 - 13:25	Oral presentations - Session 2	
13:30 - 14:30	Symposium * - Lunch box  With the institutional support of ABBVIE Morocco Management of ocular involvement in Behçet's disease	M. Khairallah (Tunisia)/ L. Essaadouni (Morocco)
14:45 - 16:30	Scientific Session 3 : Ocular Disease Chairs : A. Moutaouakil (Morocco), D. Saadoun (France)	
14:45 - 15:05	What is and what is not ocular Behçet's disease	M. Khairallah (Tunisia)
15:05 - 15:25	Evaluation of activity in ocular Behçet's disease	B. Bodagui (France)
15:25 - 15:45	Treatment of ocular Behçet's disease in 2024	I. Tugal-Tutkun (Turkey)
15:45 - 16:30	Oral presentations - Session 3	
16:30 - 17:00	Coffee break 	

* online registration required

17h00 - 18:45

Scientific Session 4 : Neurologic Disease

Chairs : B. Wechsler (France), F. Belahcen (Morocco)

17:00 - 17:20

Neurological involvement in Behçet's syndrome: clinical features, diagnosis.

D. Kidd (UK)

17:20 - 17:40

Treatment and outcome in neuro-Behçet's

D. Saadoun (France)

17:40 - 18:00

Unmet needs in Neuro-Behçet's

D. Kidd (UK)

18:00 - 18:45

Oral presentations - Session 4

19:00 - 19:30

General assembly

19:00

Poster tour

20:30

Welcome Cocktail 

Thursday 19th September 2024

07:45 - 08:45

Meet the expert: clinical cases of

▶ **Neurological :**

F. Belahcen (Morocco), B. Wechsler (France) - room Menara

▶ **Ocular :**

O. Berbich (Morocco), FZ. Alaoui (Morocco) - Room Ourika

▶ **Vascular :**

Z. Tazi Mezalek (Morocco), G. Emmi (Italy) - Room Asni

▶ **Mucocutaneous :**

C. Zouboulis, (Germany) - room Imlil 1

▶ **Articular :**

L. Essaadouni (Morocco), J. van Laar (Netherlands) - Room Imlil 2

09:00 - 09:40

Special Opening Lecture

Chairs : P. Cacoub (France), Z. Tazi Mezalek (Morocco)

From Behçet's disease to canker sores: the genetic architecture of autoinflammation

D. Kastner (USA)

09:45 - 11:30

Scientific Session 5 : Vascular Behçet

Chairs : Z. Tazi Mezalek (Morocco), P. Cacoub (France)

09:45 - 10:05

Clinical vascular phenotype

G. Emmi (Italy)

10:05 - 10:25

Treatment of vascular Behçet's disease

G. Hatemi (Turkey)

10:25 - 10:45

Pulmonary and cardiac Behçet's disease

E. Seyahi (Turkey)

10:45 - 10:55

Assessment of asymptomatic vascular disease with imaging


in Behçet's : controversial issues

H. Direskeneli (Turkey)

10:55 - 11:30

Oral presentations - Session 5

11:30 - 11:50

Coffee break 

11:50 - 13:45

Scientific Session 6 : Muco-cutaneous Behçet's disease

Chairs : F. Allali (Morocco), A. Altenburg (Germany)

11:50 - 12:10

Skin lesions in Adamantiades Behçet's disease

C. Zouboulis (Germany)

12:10 - 12:30

Oral health in Behçet's disease

F. Fortune (UK)

12:30 - 12:50

Gastrointestinal manifestations of Behçet's disease: diagnosis and treatment

JH. Cheon (Korea)

12:50 - 13:10

Musculoskeletal disorders: what is and what is not Behçet's disease

K. Echchilali (Morocco)

13:10 - 13:45

Oral presentations - Session 6

13:50 - 14:40

Symposium * – Lunch box 🍴

G. Emmi (Italy) / P. Cacoub (France)

With the institutional support of **Afric-Phar Morocco**

Venous thrombosis in Behcet's disease : what is the optimal treatment ?

14:45 - 18:50

Scientific Session 7 - Diagnosis and outcomes in Behçet's disease

Chairs : K. Bouayad (Morocco), M. Smiti (Tunisia)

14:45 - 15:05

Classification or diagnostic criteria in Behçet's disease?

F. Alibaz Oner (Turkey)

15:05 - 15:25

Paediatric Behçet's disease: diagnosis and classification

I. Koné-Paut (France)

15:25 - 15:45

Developing outcome measures in Behcet's disease

Y. Yazici (USA)

15:45 - 16:05

Treat to target objective in Behcet's disease. Is it realistic?

G. Hatemi (Turkey)

16:05 - 16:50

Oral presentations - Session 7

16:50 - 17:15

Coffee break ☕

17:15 - 18:45

Poster tour

20:30

Congress dinner 🍷

Friday 20th September 2024

07:45 - 08:45

Meet the expert: clinical cases.

▶ **Neurologic :**

K. Serraj (Morocco), M. Smiti (Tunisia), N. Kissani (Morocco) - **Room Menara**

▶ **Ocular :**

H. Harmouche (Morocco), M. Khairallah (Tunisia) - **Room Ourika**

▶ **Vascular :**

B. Lekehel (Morocco), P. Cacoub (France) - **Room Asni**

▶ **Mucocutaneous :**

M. Bourkia (Morocco), A. Altenburg (Germany) - **Room Imlil 1**

▶ **Gastroenterology :**

JH. Cheon (Korea), M. Benazzouz (Morocco) - **Room Imlil 2**

▶ **Pediatrics :**

K. Bouayad (Morocco), I. Koné-Paut (France) - **Room Ouirgane**

09:00 - 09:40

Special Lecture : Behçet's disease in 2030

A. Gul (Turkey)

Chairs : F. Fortune (UK), FZ. Alaoui (Morocco)

09:45 - 11:30

Scientific Session 8 : Old drugs/new drugs in Behçet's disease

Chairs : N. Hajjaj Hassouni (Morocco), G. Hatemi (Turkey)

09:45 - 10:05

Is there still a place for immunosuppressant's in Behçet's disease

Y. Yazici (USA)

10:05 - 10:25

Anti-TNF alpha, the new "corticosteroids" in Behçet's disease

P. Sfikakis (Greece)

10:25 - 10:45

Interleukins and anti-interleukins in Behçet's disease

JAM. Van Laar (Netherlands)

10:45 - 11:15

Coffee break ☕

10:15 - 12:00

Oral presentations - Session 8

12:00 - 12:30

Announcement of Posters prizes

Closure of the 20th ICBD, welcome to the 21th ICBD

Wednesday 18th September 2024

18:30 - 19:30

Patients program

(Meeting room TBC)

S. Talarico (Italy), L. Essaadouni (Morocco)

Thursday 19th September 2024

18:30 - 19:30

Patients program

(Meeting room TBC)

S. Talarico (Italy), L. Essaadouni (Morocco)

Oral presentation sessions

Wednesday 18th September 2024

► 10:35 - 11:20 Session 1

- **CO1.1 - The Relationship Between the NETosis Findings and Disease Activity in Behçet Disease** E. Bektas, R. Deniz, Z. Emrence, S. S. Ekmekci, N. Abaci, S. Amikishiyev, Y. Yalcinkaya, BA. Esen, M. Inanc, A. Gül. Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine - **Turkey**
- **CO1.2 - The Mevalonate Pathway Metabolite Farnesyl Pyrophosphate Induces Neutrophil Hyperactivation via the TRPM2 Calcium Channel in Behçet's Disease** W. Zheng, M. Zhang, N. Kang, X. Yu, J. Liu, H. Chen, W. Liu Peking Union Medical College Hospital/ Chinese Academy of Medical Sciences - **China**
- **CO1.3 - PDE4 inhibitor mitigates activated CD8+ T cells through NF-κB signaling in Behçet's syndrome** A. Lejoncour, P. Régnier, A. Maciejewski-Duval, P. Cacoub, D. Saadoun Department of Internal Medicine and Clinical Immunology, APHP, Paris, **France**
- **CO1.4 - Increased granzyme K+ CD8+ senescent T cells in Behçet's disease** H. Lee, SJ Lee, YJ. Park, S. Park, ES. Lee Department of Dermatology, Ewha Womans University College of Medicine - **Korea**
- **CO1.5 - Enhanced Response to Stimulation of γδ T cells induces plasma B cells in patients with Behçet's syndrome** S. Mohammed, A. Alkhalifah, R. Mirza, S. Okinedo, A. Bibi, F. Fortune, F. Flores-Borja Institute of Dentistry, QMUL - Faculty of Medicine, London - **UK**

► 12:45 - 13:25 Session 2

antiphospholipid syndrome

- **CO2.1 - A. Bettiol**, G. Bagni, F. Di Patti, E. Lastraioli, M. Radin, S. Sciascia, D. Prisco, A. Arcangeli, G. Emmi Department of Experimental and Clinical Medicine, University of Florence, Florence, **Italy**.
- **CO2.2 - HLA-B51 Positivity Correlates with Symptom Completeness from Recurrent Aphthous Stomatitis to Complete Behçet's Disease** BH. Lee, KB. Chung, H. Jang, DY. Kim Department of Dermatology, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of **Korea**
- **CO2.1 - Epigenetic regulation of thrombo-inflammation in Behçet and**
- **CO2.3 - Association of HLA-B5, HLA-B51, and HLA-B27 with clinical manifestations in Iranian Behçet's Disease patients** M. Mahalleh, M. Alikhani Rheumatology Research Center, Tehran University of Medical Sciences, **Iran**
- **CO2.4 - Influence of sex on Behçet's Disease phenotypes: Data from the International AIDA Network Behçet's Disease Registry** J. Sota, G. Ragab, I. AlMaglouth, G. Lopalco, A. Tufan, H. Direskeneli, A. Hinojosa-Azaola, HAM. Giardini, P. Sfrikakis, et al. Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, University of Siena, **Italy**.
- **CO2.5 - Clinical features and phenotypic similarities of patients with familial Behçet's Disease** F. Alibaz-Oner, K. Abacar, AE. Boncukcuoğlu, R. Deniz, BC. Uludoğan, D. Kaş, E. Alkan, G. Kaya, T. Bozkurt, NŞ. Yaşar-Bilge, C. Bes, T. Kaşifoğlu, D. McGonagle, T. Ergun, H. Direskeneli Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, **Turkey**

► 15:45 - 16:30 Session 3

- **CO3.1 - Phenotypic and functional analysis of NK Cell populations in Behçet's uveitis: effects of adalimumab treatment and comparative inflammatory responses with axial ankylosing spondylitis** F. Esen, A. Kokoglu, C. Cetin, O. Turkyilmaz, NA. Ceylan, M. Oray, H. Direskeneli, I. Tugal-Tutkun, A. Gul, G. Deniz, EA. Çetin Aziz Sancar Institute of Experimental Medicine - Institute of Graduate Studies in Health Sciences - Department of Ophthalmology - Medeniyet University - Istanbul University, **Turkey**
- **CO3.2 - The BD immune landscape exhibits a universal NF-κB-mediated hyperactivation pattern with cell-specific TNFAIP3 responses and a superimposed IFN-regulated endotype** J. Nowatzky, Y. Ozguler, O. Manches, D. Ucar, Z. Lin, M. Oray, A. Khodadadi-Jamayran, I. Tugal-Tutkun, A. Tsirigos, G. Hatemi Department of Medicine, Division of Rheumatology, New York Grossman School of Medicine, **USA**
- **CO3.3 - Impact of HLA-B51 on uveitis and retinal vasculitis: data from the AIDA International Network Registries on ocular inflammatory disorders** J. Sota, G. Lopalco, S. Guerriero, G. Ragab, I. AlMaglouth, M. Govoni, P. Sfrikakis, M. Frassi, A. Vitale, RC. Kardas, P. Triggianese, AA. Aboabat, M. Piga, et al. Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, University of Siena, **Italy**.
- **CO3.4 - Common femoral vein wall thickness is a useful diagnostic tool to differentiate ocular Behçet's Disease from other inflammatory uveitis.** F. Alibaz-Oner, SK. Agackiran, E. Kardes, A. Agackiran, H. Direskeneli Vasculitis Clinic, Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, **Turkey**
- **CO3.5 - Long-term effect of anti-TNF therapy in patients with Behçet uveitis** N. Yalçındağ, T. Pinar Akkale, A. Sultanova Department of Ophthalmology, Ankara University, Ankara, **Turkey**

► 18:00 - 18:45 Session 4

- **CO4.1 - Prospective evaluation of neurological presentations to a national Neuro-Behçet clinic; migraine is the commonest neurological complaint in Behçet's Disease** M. Ghadiri-Sani, S. Broadhurst, J. Ramachandran Nair, R. Moots The Walton Centre NHS Foundation Trust, Liverpool, **UK**
- **CO4.2 - Neuro-Behçet in its parenchymal form: study of clinical, radiological, therapeutic, and evolutionary profile** G. Es-sayeh, MF. Belahsen Neurology Department of CHU HASSAN II, Faculty of Medecine Fez, University Sidi Mohamed Ben Abdellah, **Morocco**.
- **CO4.3 - The factors associated with cognitive disorders in Behçet's Disease patients** T. Lisitsyna, P. Ovcharov, K. Nurbaeva, D. Veltishchev, T. Reshetnyak Nasonova Research Institute of Rheumatology, - Serbsky National Medical Research for Psychiatry and Narcology, Moscow Research Institute of Psychiatry, **Russia**.
- **CO4.4 - Evaluation of optic disk and parafoveal parameters in Neuro-Behçet patients without ocular involvement using optical coherence tomography angiography** ZŞ. Akbaş, U. Uygunoğlu, D. Uçar Department of Ophthalmology, Cerrahpasa Medical Faculty, Istanbul University - Cerrahpasa, **Turkey**.
- **CO4.5 - Arterial involvement in Neurobehçet Syndrome: Vessel wall imaging as a diagnostic marker** U. Uygunoglu, EK. Kizilkilic, AK. Karaman, N. Erener, B. Korkmazer, S. Arslan, O. Kizilkilic, E. Seyahi, A. Siva Behçet's Disease Research Center - Department of Neurology, Istanbul University - Cerrahpasa, School of Medicine, **Turkey**

Thursday 19th September 2024

► 10:55 - 11:30 Session 5

- **CO5.1 - Pulmonary involvement in Behçet's syndrome : a systematic review of the literature** AK. Tumay, SE. Nurcan, E. Seyahi Division of Rheumatology, Department of Internal Medicine, Behçet's Disease Research Centre Istanbul University-Cerrahpasa, School of Medicine, Istanbul, **Turkey**.
- **CO5.2 - Diagnostic value of vein wall thickness measurement for patients with suspected Behçet Syndrome** SN. Esatoglu, R. Alcin, Y. Kayadibi, A. Kahveci, I. Adaletli, Y. Ozguler, M. Melikoglu, G. Hatemi Division of Rheumatology, Department of Internal Medicine, Behçet's Disease Research Centre Istanbul University-Cerrahpasa, School of Medicine, Istanbul, **Turkey**.
- **CO5.3 - Stasis ulcer in Behçet's syndrome : a common but difficult to manage complication** A. Karakoc, Y. Ozguler, A. Ozdede, ZA Ferhanoglu, Z. Kutlubay, SH. Karagoz, SN. Esatoglu, G. Hatemi, M. Melikoglu, E. Seyahi Division of Rheumatology, Department of Internal Medicine, Behçet's Disease Research Centre Istanbul University-Cerrahpasa, School of Medicine, Istanbul, **Turkey**.
- **CO5.4 - Direct oral anticoagulants in patients with vascular involvement of Behçet' s Disease: a single center experience** F. Alibaz-Öner, D. Kocakaya, Ü. Karayıldız, S. Karakurt, H. Direskeneli Vasculitis Clinic, Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, **Turkey**

► 13:10 - 13:45 Session 6

- **CO6.1 - Replication of the 23-Valent polysaccharide pneumococcal vaccine-induced skin pathergy test in an independent cohort of patients with Behçet Disease** R. Deniz, A. Gül Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, Istanbul, **Turkey**.
- **CO6.2 - Skin microbiome shows differences between pathergy positive and negative patients with Behçet's syndrome** Y. Ozguler, B. Sarac, A. Kalkanci, E. Kilic, EA. Sahin, G. Hatemi Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Istanbul, **Turkey**.
- **CO6.3 - Axial spondyloarthritis in patients with gastrointestinal involvement of Behçet Syndrome** G. Hatemi, M. Ozturk, SN. Esatoglu, I. Hatemi, AF. Celik, OA. Kargin, A. Ozz, E. Yilmaz, D. Ucar, M. Melikoglu, H. Yazici, I. Adaletli Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Istanbul, **Turkey**.
- **CO6.4 - Saliva proteome analysis in Behçet's Disease: ELISA validation** A. Poveda-Gallego, G. Wallace, S. Rauz, I. Chapple, M. Grant Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; School of Dentistry, Dental Hospital, Birmingham Community Health Foundation Trust, **UK**.
- **CO6.5 - Patients with oral ulcer display high levels of salivary acidic glycoproteins in Behçet's Syndrome** G. Mumcu, HC. Aras, BP. Akmansoy, B. Sari, C. Akmansoy, I. Tatli, F. Türe-Özdemir, F. Alibaz Öner, N. Inanc, T. Ergun, N. Bostanci, H. Direskeneli, F. Fortune Department of Health Management, Faculty of Health Sciences, Marmara University, Istanbul, Turkey. The London School of Medicine and Dentistry, Centre Immunobiology and Regenerative Medicine, Queen Mary University of London, **UK**.

► **16:05 - 16:50** **Session 7**

- **CO7.1 - Prospective follow-up of patients with suspected Behçet's Disease: First results of an inception cohort.** F. Alibaz-Oner, O. Karakok, S. Kutlug-Agackiran, R. Ergelen, T. Ergun, H. Direskeneli. Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, **Turkey**
- **CO7.2 - Major organ involvement is lower in young male patients with Behçet Disease during ten years prospective follow-up compared to retrospective cohorts** F. Alibaz-Oner, SK Agackiran, B. Aldag, E. Karatay, T. Ergun, H. Direskeneli Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, **Turkey**
- **CO7.3 - Identifying clinical clusters in Behcet Syndrome: a latent class analysis of a large retrospective cohort.** S. Chadli, H. Khibri, M. Bourkia, N. Moatassim, W. Ammouri, M. Maamar, H. Harmouche, M. Adnaoui, R. Abouqal, Z.Tazi Mezalek Internal Medicine department - Ibn Sina University Hospital, Mohammed V University, Rabat, **Morocco**
- **CO7.4 - A systematic review of outcome measures used to assess the core domains for clinical trials in Behçet Syndrome** Y.Ozguler, SN. Esatoglu, PA. Merkel, B. Shea, H. Direskeneli, A. Mahr, R. Christensen, G. Hatemi Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Istanbul, **Turkey.**
- **CO7.5 - Comparison of the 2015 pediatric diagnostic criteria for Behcet's Disease with the 2014 and 1990 International Study Group Diagnostic Criteria.** K. Bouayed, K. El Ouassifi Department of Pediatric Rheumatology and Internal Medicine, A. Harouchi Mother-Child Hospital, Ibn Rochd University Hospital, Hassan II University, Casablanca, **Morocco.**

Friday 20th September 2024

► **10:45 - 11:00** **Session 8**


- **CO8.1 - Medication adherence and compliance in patients with Behçet's Syndrome** B. Gokani, S. Sacoor, A. Senusi, N. Ul-Ain, C. Tran, Y. Jagatiya, A. Bibi, N. Wakjira, J. Christians, F. Fortune The London School of Medicine and Dentistry, Centre Immunobiology and Regenerative Medicine, Queen Mary University of London, London Behçet's Centre of Excellence, Royal London Hospital, Bart's Health - **UK.**
- **CO8.2 - Characterization of a multicenter cohort of patients with Behçet's Syndrome treated with Methotrexate: efficacy and safety.** C. Moriano Morales, M. Retuerto Guerrero, JL. Martín-Varillas, J. Narváez, R. Fornons Servent, CM. Vilchez, J. Graña Gil, U. Couto Lareo, C. San José-Méndez, M. Garijo Bufort, E. Díez Álvarez Department of Rheumatology, Complejo Asistencial Universitario de León, **Spain.**
- **CO8.3 - Retrospective study of the efficacy of apremilast for uveitis in Behçet's Disease ocular lesions** M. Takeuchi, A. Meguro, J. Shindo, N. Yamada, Y. Kirino, Y. Soejima, L. Hirahara, Y. Lizuka, N. Mizuki Department of Ophthalmology, Yokohama City University School of Medicine, Yokohama, **Japan.**
- **CO8.4 - De Novo manifestations during Adalimumab treatment in Behçet Syndrome** SN. Esatoglu, O. Sonmez, D. Ucar, E. Kaymaz, Y. Ozguler, S. Ugurlu, E. Seyahi, M. Melikoglu, I. Fresko, V. Hamuryudan, U. Uygunoglu, Z. Kutlubay, Al. Hatemi, AF. Celik, G. Hatemi Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, **Turkey.**
- **CO8.5 - Feasible drug-free remission for more than 5 years following withdrawal of successful long-term anti-TNF treatment in Behcet's disease: a re-appraisal of a single-center longitudinal outcome study** A. Arida, N. Markomichelakis, G. Fragoulis, PP. Sfikakis Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, Medical School, National and Kapodistrian University of Athens, **Greece.**

Sponsor Diamant

 **NOVARTIS**

 **abbvie**

 **Janssen**
PHARMACEUTICAL COMPANIES
OF Johnson & Johnson

 **AstraZeneca**

 **axess
pharma**

 **أفريك - فار**
AFRIC-PHAR

Sponsor Platine

 **AMGEN**

 **hikma.**
مؤسسة حكيم فارما
PRO:OPHARM S.A.

 **AMANYS
PHARMA**

 **سوطيما**
Sothema
Des énergies unies pour la vie

 **sanofi**

 **GSK**

Sponsor Gold

 **Boehringer
Ingelheim**

 **PHARMA 5**

 **PHARMAPROM**

 **Roche**

 **Biocon**  **Mylan®**

Sponsor Silver

 **SERVIER**
moved by you

 **COOPER
PHARMA**

 **Health**

 **Laprophan**
لاروفان

 **InQure®**

 **VIATRIS**

 **IBERMA**
Depuis 1993

 **aspen
HEALTH CARE**

 **GÉNÉRATION
SANTÉ**
Laboratoire Pharmaceutique

 **h.i by KELIX bio**

 **MSD**
INVENTING FOR LIFE

 **Versalya**
La femme et son enfant

 **tecnimed**